The effect of interleukin-6 level at the time of hospitalisation on erectile functions in hospitalised patients with COVID-19
Andrologia, cilt.54, sa.1, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 54 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.1111/and.14285
- Dergi Adı: Andrologia
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
- Anahtar Kelimeler: COVID-19, erectile dysfunction, IIEF-5, interleukin-6
- İstanbul Medipol Üniversitesi Adresli: Evet
Özet
We evaluated the relationship between erectile dysfunction (ED) and IL-6 levels in males with COVID-19. The study included 80 male patients aged 30–45 years who were hospitalised due to COVID-19. The International Index of Erectile Function (IIEF-5) questionnaire was used to assess erectile function. The IIEF-5 questionnaire was re-administered at a 3-month control visit after discharge, and the change score from baseline was recorded. The patients were divided into three groups according to the IIEF-5 score at 3 months as Group 1 (severe ED), Group 2 (moderate ED) and Group 3 (no ED), and into two groups according to IL-6 level at the time of admission as Group A (IL-6 ≤ 50 ng/ml) and Group B (IL-6 > 50 ng/ml). The change in the IIEF-5 score (p <.001) was significantly greater in Group B than in Group A. There was also significant difference in IL-6 between Group 1 and Group 2 (p =.008). The correlation analysis revealed a moderate correlation between IL-6 level and the change in IIEF-5 score and D-dimer level (r:0.529, p <.001) and a weak correlation between IL-6 level and FSH (r:0.309, p =.005). The present study suggests that elevated IL-6 levels in male patients hospitalised due to COVID-19 might be related to the risk of developing ED.